The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Abstract
BACKGROUND: Skeletal complications are a major clinical manifestation of multiple myeloma. These complications are caused by soluble factors that stimulate osteoclasts to resorb bone. Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bone resorption. METHODS: Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy. The patients were stratified according to whether they were receiving first-line (stratum 1) or second-line (stratum 2) antimyeloma chemotherapy at entry into the study. Skeletal events (pathologic fracture, irradiation of or surgery on bone, and spinal cord compression), hypercalcemia (symptoms or a serum calcium concentration > or = 12 mg per deciliter [3.0 mmol per liter]), bone pain, analgesic-drug use, performance status, and quality of life were assessed monthly. RESULTS: Among 392 treated patients, the efficacy of treatment could be evaluated in 196 who received pamidronate and 181 who received placebo. The proportion of patients who had any skeletal events was significantly lower in the pamidronate group (24 percent) than in the placebo group (41 percent, P < 0.001), and the reduction was evident in both stratum 1 (P = 0.04) and stratum 2 (P = 0.004). The patients who received pamidronate had significant decreases in bone pain and no deterioration in performance status and quality of life. Pamidronate was tolerated well. CONCLUSIONS: Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beahrs, O. H., & Henson, D. E. (1992) · Medical Entomology and Zoology · Cited by 2,460
Measuring the quality of life of cancer patients
Spitzer, W. O., Dobson, A. J., Hall, J., Chesterman, E., Levi, J., Shepherd, R., Battista, R. N., & Catchlove, B. R. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90058-8 · Cited by 1,528
Parfitt, A. M. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240550303 · Cited by 1,001
Tong, D., Gillick, L., & Hendrickson, F. R. (1982) · Cancer · doi:10.1002/1097-0142(19820901)50:5<893::aid-cncr2820500515>3.0.co;2-y · Cited by 790
Multiple myeloma; a review of 26 cases.
Harnagel, E. E., Kleinberg, I., Kahlstrom, S. C., & Rhudy, F. V. (1957) · PubMed · Cited by 682
Hayward, J. L., Carbone, P. P., Heuson, J.-C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · Cancer · doi:10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f · Cited by 623
Stashenko, P., Dewhirst, F. E., Peros, W. J., Kent, R. L., & Ago, J. M. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.5.1464 · Cited by 525
Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
Lahtinen, R., Laakso, M., Palva, I., Elomaa, I., & Virkkunen, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93075-x · Cited by 385
Nussbaum, S. R., Younger, J., Vandepol, C. J., Gagel, R. F., Zubler, M. A., Chapman, R., Henderson, I. C., & Mallette, L. E. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90282-t · Cited by 228
Effects of Dichloromethylene Diphosphonate on Skeletal Mobilization of Calcium in Multiple Myeloma
Siris, E. S., Sherman, W. H., Baquiran, D. C., Schlatterer, J. P., Osserman, E. F., & Canfield, R. E. (1980) · New England Journal of Medicine · doi:10.1056/nejm198002073020602 · Cited by 185
Bisphosphonates: A New Class of Drugs in Diseases of Bone and Calcium Metabolism
Fleisch, H. (1989) · Recent Results in Cancer Research · doi:10.1007/978-3-642-83668-8_1 · Cited by 182
Effect of daily etidronate on the osteolysis of multiple myeloma.
Belch, A. R., Bergsagel, D. E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J., Johnston, D., & Zee, B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.8.1397 · Cited by 178
INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)
Van Breukelen, F. J. M., Bijvoet, O., & Van Oosterom, A. T. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91319-9 · Cited by 173
Manual for Staging of Cancer, 3rd edition
Beahrs, O. H., Henson, D. E., Hutter, R. V. P., & Myers, M. H. (1988) · American Journal of Clinical Oncology · doi:10.1097/00000421-198812000-00027 · Cited by 147
Mechanisms of osteolytic bone destruction
Mundy, G. R. (1991) · Bone · doi:10.1016/8756-3282(91)90057-p · Cited by 131
Bone destruction and hypercalcemia in plasma cell myeloma.
Mundy, G. R., & Bertolini, D. R. (1986) · PubMed · Cited by 88
Treatment of bone metastases from breast cancer and myeloma with pamidronate.
Thiébaud, D., Leyvraz, S., von Fliedner, V., Perey, L., Cornu, P., Thiébaud, S., & Burckhardt, P. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90056-j · Cited by 75
Osteoclast inhibition for the treatment of bone metastases
Coleman, R. E., & Purohit, O. P. (1993) · Cancer Treatment Reviews · doi:10.1016/0305-7372(93)90028-p · Cited by 48
Ferretti, J. L., Cointry, G. R., Capozza, R. F., Montuori, E., Ej, R., & Lloret, A. P. (1990) · Bone and Mineral · doi:10.1016/0169-6009(90)90020-g · Cited by 47
Cohen, H. J., Silberman, H., Tornyos, K., & Bartolucci, A. (1984) · Blood · doi:10.1182/blood.v63.3.639.639 · Cited by 45
Controversies in the treatment of plasma cell myeloma
Bergsagel, D. E. (1985) · Postgraduate Medical Journal · doi:10.1136/pgmj.61.712.109 · Cited by 25
Aranko, K., arvi, H. H., President, R. D. V., Humphreys, M., Drake, J., & Lawton, W. A. (1995) · Bone · doi:10.1016/8756-3282(95)90127-2 · Cited by 2
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0210 · Cited by 1,920
Metadata
- Authors
- Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., Blacklock, H. A., Bell, R., Simeone, J., Reitsma, D. J., Heffernan, M., Seaman, J., & Knight, R. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1996-02-22
- Volume
- 334
- Issue
- 8
- Pages
- 488-493
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2325302070
- Cited by
- 1,081
- References
- 23
- FWCI
- 22.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.